Evaluation of the Efficacy and Safety of Mepivacaine on the Neurological Sequelae of Cerebral Infarction

Who is this study for? Patients with Acute Ischemic Stroke
What treatments are being studied? Carbocaine Injectable Product
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

A patient, suffering from cortical blindness after a bi-occipital infarction 1 year earlier, regained near-normal vision in the right visual hemifield a few minutes after subcutaneous administration of mepivacaine. The effect was maintained for several days, and was repeated with each injection of mepivacaine. This clinical improvement is associated with functional changes in the peri-lesional areas on resting-state functional MRI. The investigator team hypothesizes that in some patients with chronic neurological symptoms of stroke, the investigator team will observe a favorable response to subcutaneous mepivacaine injection.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Ischemic stroke more than 30 days old

• Age between 18 and 85 years old

• At least one deficit among:

• motor deficit: score \< 56 on the Fugl-Meyer scale

• aphasia: score ≥4 on the Aphasia Rapid Test,

• presence of a clinically observable visual scotoma

• Having given their written consent

• Be affiliated with a social security scheme, Universal Medical Coverage (CMU) or any equivalent scheme

Locations
Other Locations
France
Hôpital Pitié Salpetrière
RECRUITING
Paris
Contact Information
Primary
COHEN Laurent, PUPH
laurent.cohen@aphp.fr
142161801
Time Frame
Start Date: 2022-06-22
Estimated Completion Date: 2024-06-22
Participants
Target number of participants: 38
Treatments
Experimental: Mepivacaine arm
mepivacaine injection
Related Therapeutic Areas
Sponsors
Leads: Assistance Publique - Hôpitaux de Paris

This content was sourced from clinicaltrials.gov